SGMS2 and breast carcinoma: SMS2 increased the expression of TGF- β1 by upregulating SM, which subsequently activated the TGF-β/Smad signalling pathway and promoted EMT in breast cancer cells, thus increasing the migration and invasiveness of breast cancer cells